ValuentumAd

Official PayPal Seal














Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Feb 23, 2017
Is Clean Energy Just Burning Cash?
Image Source: Chuck Coker. Clean or renewable energy sources will undoubtedly be a part of how we generate power in the future, but how investible is the space? The answer is largely dependent on your risk tolerance.
Feb 23, 2017
PBMs: Express Scripts and CVS’ Looming Victory?
Image Source: Victor. We’re expecting a big win at CVS in coming years, and it may come at the expense of Express Scripts.
Feb 23, 2017
3 Critical Drug Approvals For Your Radar
Image Source: Neurocrine Biosciences.  What can investors expect when it comes to imminent drug approvals? Let’s cover three important ones.
Feb 20, 2017
Dividend Increases/Decreases for the Week Ending February 17
Let's take a look at companies raising/lowering their dividends this week.
Feb 18, 2017
Johnson & Johnson's Oncology Division A Force to Be Reckoned With
Image Source: Open Grid Scheduler. Healthcare and consumer staples giant Johnson & Johnson is a core holding in both newsletter portfolios. Let’s take a deep dive into one of its key sources of growth, its ‘Pharmaceutical’ segment.
Feb 17, 2017
Cisco Accelerating Recurring Revenue Base, Raises Dividend Double Digits
Image Source: Brandon Leon. Newsletter portfolio holding Cisco continues to transition its business to a software and subscription-based model. Let’s take a look its progress as of its second quarter of fiscal 2017.
Feb 15, 2017
Gilead Sciences Continues Its Meltdown
Image Source: Gilead. Valuentum has been out of Gilead in the newsletter portfolios for some time. As the Best Ideas Newsletter portfolio continues to make new highs, Gilead continues to set new 52-week lows. This is the power of “portfolio thinking,” something we've been preaching for a long time.
Feb 15, 2017
These Medical Instruments Won’t Heal Your Portfolio
The medical instruments industry is a group characterized in part by diversity, and as such, there are ideas of all shapes and sizes. Let’s dig into two overvalued companies in the space and what put them in their current positions.
Feb 15, 2017
Amazon’s Future May Be Rich, But So Is Its Valuation
Amazon continues to disrupt the traditional retail landscape and its cloud-based services are gaining momentum, but shares look to be running ahead of its fundamental trajectory. Let’s take a look at its most recent quarter.
Feb 14, 2017
Is AbbVie a Value Trap?
Image Source: Express Scripts. With uncertainty surrounding the patent of blockbuster drug Humira, AbbVie is looking to deliver another success story from its pipeline. Is it headed for a patent cliff? Let’s take a look.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.